目的 探讨安胃疡胶囊联合替普瑞酮胶囊治疗胃溃疡的临床疗效。方法 选取2017年6月-2019年6月在驻马店市中医院治疗的102例胃溃疡患者，根据用药差别分为对照组（51例）和治疗组（51例）。对照组患者口服替普瑞酮胶囊，50 mg/次，3次/d；治疗组在对照组基础上口服安胃疡胶囊，0.4 g/次，4次/d。两组患者均经4周治疗。观察两组患者临床疗效，比较两组患者症候积分、GQOL-74量表评分、幽门螺杆菌根除率、溃疡愈合率、胃动素（MTL）、胃泌素（GAS）、生长抑素（SS）和降钙素基因相关肽水平（CGRP）水平，以及血清血管内皮生长因子（VEGF）、白细胞介素-8（IL-8）、IL-17、高迁移率族蛋白B1（HMGB1）、基质金属蛋白酶-9（MMP-9）和前列腺素E2（PGE2）水平。结果 治疗后，对照组和治疗组临床有效率分别为80.39%、98.04%，两组比较差异有统计学意义（P<0.05）。经治疗，两组患者症候积分和GQOL-74评分均明显下降（P<0.05），且治疗组比对照组降低更明显（P<0.05）。经治疗，治疗组幽门螺杆菌根除率和溃疡愈合率均显著高于对照组（P<0.05）。经治疗，两组患者MTL、GAS、IL-8、IL-17、HMGB1、MMP-9表达均明显下降（P<0.05），CGRP、SS、VEGF和PGE2水平均明显升高（P<0.05），且治疗后治疗组这些指标水平明显好于对照组（P<0.05）。结论 安胃疡胶囊联合替普瑞酮胶囊治疗胃溃疡可显著促进患者临床症状改善，改善患者生活质量、胃肠激素水平，促进溃疡愈合。

Objective To explore the clinical efficacy of Anweiyang Capsules combined with teprenone in treatment of gastric ulcer. Methods Patients (102 cases) with gastric ulcer in Zhumadian TCM Hospital from June 2017 to June 2019 were divided into control (51 cases) and treatment (51 cases) groups based on different treatments. Patients in the control group were po administered with Teprenone Capsules, 50 mg/time, three times daily. Patients in the treatment group were po administered with Anweiyang Capsules on the basis of the control group, 0.4 g/time, four times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the symptom scores, the GQOL-74 scale scores, the eradication rate of Hp, ulcer healing rate, and the level of MTL, GAS, SS, CGRP, VEGF, IL-8, IL-17, HMGB1, MMP-9 and PGE2 in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 80.39% and 98.04%, respectively, and there were differences between two groups (P < 0.05). After treatment, the symptom scores and GQOL-74 scale scores in two groups were significantly decreased (P < 0.05), and these scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the eradication rate of Hp and ulcer healing rate in the treatment group was significantly higher than that in the control group (P < 0.05). After treatment, the levels of MTL, GAS, IL-8, IL-17, HMGB1, and MMP-9 in two groups were significantly decreased (P < 0.05), but the levels of CGRP, SS, VEGF, and PGE2 in two groups were significantly increased (P < 0.05), and these indexes in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Anweiyang Capsules combined with teprenone in treatment of gastric ulcer can significantly improve the clinical symptoms, improve the quality of life and gastrointestinal hormone level, and promote ulcer healing.

R975